Abstract
With political will, modest financial investment and effective technical assistance, public sector hepatitis C virus (HCV) programmes can be established in low- and middle-income countries as a first step towards elimination. Seven countries, with support from the Clinton Health Access Initiative (CHAI) and partners, have expanded access to HCV treatment by combining programme simplification with market shaping to reduce commodity prices. CHAI has supported a multipronged approach to HCV programme launch in Cambodia, India, Indonesia, Myanmar, Nigeria, Rwanda and Vietnam including pricing negotiations with suppliers, policy development, fast-track registrations of quality-assured generics, financing advocacy and strengthened service delivery. Governments are leading programme implementation, leveraging HIV programme infrastructure/financing and focusing on higher-HCV prevalence populations like people living with HIV, people who inject drugs and prisoners. This manuscript aims to describe programme structure and strategies, highlight current commodity costs and outline testing and treatment volumes across these countries. Across countries, commodity costs have fallen from >US$100 per diagnostic test and US$750–US$900 per 12-week pan-genotypic direct-acting antiviral regimen to as low as US$80 per-cure commodity package, including WHO-prequalified generic drugs (sofosbuvir + daclatasvir). As of December 2019, 5900+ healthcare workers were trained, 2 209 209 patients were screened, and 120 522 patients initiated treatment. The cure (SVR12) rate was >90%, including at lower-tier facilities. Programmes are successfully implementing simplified, decentralised public health approaches. Combined with political will and affordable pricing, these efforts can translate into commitments to achieve global targets. However, to achieve elimination, additional investment in scale-up is required.
Funder
UK Department for International Development
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference29 articles.
1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Lancet Gastroenterol Hepatol,2017
2. World Health Organization . Guidelines for the care and treatment of persons diagnosed with chronic HCV infection. Geneva, Switzerland, 2018.
3. World Health Organization . Combating hepatitis B and C to reach elimination by 2030, 2016.
4. AASLD, EASL, APASL, ALEH . Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure, 2019.
5. Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献